Anticoagulants - Global Strategic Analysis

Description: This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin).

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 51 companies including many key and niche players such as:

Abbott India Limited
Aspen Holdings
Bayer Healthcare AG
Boehringer Ingelheim
Bristol-Myers Squibb Company

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Oral Anticoagulants
Injectable Anticoagulants

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW
Anticoagulants Market Driven by Novel Oral Anti-coagulants
Safety Issues Associated with Erstwhile Market Leaders
Warfarin & Heparins
Anticoagulants
Evolution from Injectables to Oral Drugs
Conventional Oral Drugs Face the Heat
The Newer Breed of NOACs
Comparative Analysis of Warfarin and Novel Oral Anticoagulants
Table 1: Global Market for Leading Oral Drugs (2014): Percentage Market Share Breakdown of Value Sales for Eliquis, Pradaxa, Xarelto, and Others (includes corresponding Graph/Chart)
Novel Oral Drugs: Absence of Antidote & Other Concerns
Rapid Ongoing R&D on Antidote Development
Pipepline of Antidotes to Reverse Anticoagulant Action
Aging Population: Crucial Driver for Anticoagulants Market
Table 2: Global Population Statistics for 65+ Age Group (2014) (includes corresponding Graph/Chart)
Table 3: Elderly Population (65+ Years) Worldwide by Geographic Region on the Basis of Economic Status (2000 & 2025): % of Total Population for More Developed Countries, Less Developed Countries and Least Developed Countries (includes corresponding Graph/Chart)
Table 4: Life Expectancy for Select Countries in Number of Years (2015E) (includes corresponding Graph/Chart)
Rising Stroke Statistics
An Opportunity Indicator for Anticoagulants
Global Menace of Cardiovascular Disease
Major Growth Factor
Table 5: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
Table 6: Fatalities by Heart Conditions
Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
Sizing the Market
No Immediate Threat of Generics for NOACs
Market Players
Betrixaban
The Only Other Novel Oral Drug in Pipeline

2. MARKET TRENDS & ISSUES
NICE Guidelines Promote NOAC Usage
NOACs as Alternative/Supplement to Antiplatelet Therapy
Increase in Heparin Trade Boosts the Market
NOAC Underdosing Trend Restrains Universal Acceptance
Generics Prevail in the Traditional Market
Patent Expiries of Traditional Anticoagulants in the US
Inadequate Trials Mar Pediatric Anticoagulants Market
Growing Demand for Self-Testing
LMWHs Ease Outpatient Management

3. SEGMENT ANALYSIS
Oral Anticoagulant Agents
Traditional Oral Anticoagulants
Warfarin
Coumadin
The Branded Warfarin
Advantages and Alternatives
Limitations
Novel Oral AntiCoagulants (NOAC)
Approved Indications of Various NOACs by Geographic Region
Approved Anticoagulant Agents in a Nutshell
Pradaxa (Dabigatran Etxelixate)
Pradaxa and Warfarin
A Comparative Study
Xarelto (Rivaroxaban)
Apixaban (Eliquis)
Injectable Anticoagulants
Injectable Anticoagulants- An Insight
Heparin
The Backbone of Injectable Anticoagulants
Unfractionated Heparin
Advantages and Alternatives
Limitations
Low Molecular Weight Heparins
Indications
Advantages
A Focus on Select Heparin-based Injectables
Lovenox/Clexane (enoxaparin)
Fragmin (dalteparin sodium)
Fraxiparine (nadroparin)
Innohep (tinzaparin)
Normiflo (ardeparin)
Clivarine (reviparin)
Non-Heparin Anticoagulant Injectables
An Overview
Arixtra (fondaparinux)
Angiomax (bivalirudin)
Argatroban/Novastan

4. THERAPEUTIC INDICATIONS
Venous/DVT Thrombosis Indications
Venous Thromboembolism
Deep Vein Thrombosis
Pulmonary Embolism
Orthopedic (Hip or Knee Replacement) Surgery
General Surgery
Cancer
Arterial Thrombosis Indications
Arterial Thrombosis
Acute Coronary Syndromes
Atrial Fibrillation
Unstable Angina
List of Approved Anticoagulants for Unstable Angina
Myocardial Infarction
Non ST-Segment Elevation MI
Percutaneous Transluminal Coronary Angioplasty (PTCA)
Heparin Induced Thrombocytopenia (HIT) Indications
Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
Other Indications
Hemodialysis

5. PRODUCT INTRODUCTIONS/APPROVALS
FDA Approves Pradaxa Antidote Praxbind
CFDA Approves Bayer's Xarelto
Raplixa Anticoagulant by MDCO Receives FDA Approval
Teva Launches Argatroban Injection in the US Market
BMS and Pfizer Announce Phase III Results of Apixaban
Boehringer Ingelheim Receives Priority Review by FDA for Idarucizumab BLA
FDA Grants Fast Track Designation to Perosphere's PER977
FDA Approves Savaysa/Edoxaban
FDA Approves sNDA for Eliquis
USFDA Approves Pradaxa by Boehringer Ingelheim
EC Approves Expanded Indications of Xarelto

6. RECENT INDUSTRY ACTIVITY
Bayer Collaborates with Janssen on Extended Clinical Investigation of Xarelto
Bayer to Acquire Experimental Anticoagulant from Isis Pharmaceuticals
Akers Biosciences Receives Supply Order from NovoTek for PIFA Heparin PF4
Mylan Ireland to Acquire Arixtra Generic Rights from Aspen
Merus Labs Acquires Sintrom (acenocoumarol) from Novartis AG
CMC Biologics Signs Supply Agreement with Portola Pharmaceuticals
GlaxoSmithKline Divests Thrombosis Brands to Aspen
SQI Diagnostics Partners with Algorithme Pharma on Multiplex Heparin Assay

7. FOCUS ON SELECT GLOBAL PLAYERS
Abbott India Limited (India)
Aspen Holdings (South Africa)
Bayer Healthcare AG (Germany)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb Company (US)
Eisai Inc. (US)
GlaxoSmithKline Plc. (UK)
Mitsubishi Tanabe Pharma Corporation (Japan)
Pfizer, Inc. (US)
Sanofi S.A. (France)
Teva Pharmaceutical Industries Ltd. (Israel)

8. GLOBAL MARKET PERSPECTIVE
Table 7: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 8: World Historic Review for Anticoagulants by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 9: World 14-Year Perspective for Anticoagulants by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 10: World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 11: World Historic Review for Oral Anticoagulants by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 12: World 14-Year Perspective for Oral Anticoagulants by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 13: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Injectable Anticoagulants by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 15: World 14-Year Perspective for Injectable Anticoagulants by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment
Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Injectable Anticoagulants by Product Segment
Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 18: World 14-Year Perspective for Injectable Anticoagulants by Product Segment
Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Unfractionated Heparin by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 21: World 14-Year Perspective for Unfractionated Heparin by Geographic Region/Country
Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 23: World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 24: World 14-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A. Market Analysis
Key Statistics
US: The Largest Market for Anti-Coagulants
A List of FDA Approved Anticoagulants
Atrial Fibrillation
A Key Risk Factor
Rapidly Ageing Demographics Drive Growth in the Anticoagulants Market
Table 25: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
Surge in CVD Incidence
Major Growth Factor
Table 26: CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)
Table 27: CVD in the US: Cardiovascular Disease Incidence by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart)
Table 28: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)
Lack of Public Health Funding
Table 29: US Healthcare Spending by Therapeutic Area (2014): Percentage Share Breakdown of Expenditure for Various Therapeutic Areas (includes corresponding Graph/Chart)
US Heparin Market
Heparin Trade Statistics
Table 30: The US Exports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Export Value of Leading Destination Countries (includes corresponding Graph/Chart)
Table 31: The US Imports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Import Value of Leading Countries of Origin (includes corresponding Graph/Chart)
Product Introductions/Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 32: The US Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 33: The US Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 34: The US 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

2. CANADA
A. Market Analysis
Heparin Trade Statistics
Table 35: Canadian Exports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Export Value of Leading Destination Countries (includes corresponding Graph/Chart)
Table 36: Canadian Imports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Import Value of Leading Countries of Origin (includes corresponding Graph/Chart)
B. Market Analytics
Table 37: Canadian Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 38: Canadian Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 39: Canadian 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

3. JAPAN
A. Market Analysis
Graying Population Spurs Growth of Anticoagulants

Table 40: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
Table 41: Aging Population Growth (%) in Japan: 2015E-2060P (includes corresponding Graph/Chart)
Select Key Players

B. Market Analytics
Table 42: Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 43: Japanese Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 44: Japanese 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Europe: A Major Anti-Coagulant Market
Differential Uptake of NOACs by European Countries
Table 45: European Percentage Uptake of NOACs by Country: 2014 (includes corresponding Graph/Chart)
Increasing Aging Population Boosts Demand
Table 46: Life Expectancy at 65 Years for Select Countries in Europe: 2012 (includes corresponding Graph/Chart)
Table 47: European Population by Age Group (2014): Percentage Share Breakdown of Age groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart)
LMWH: Dominant Heparin Segment in Europe

B. Market Analytics
Table 48: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country
France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 49: European Historic Review for Anticoagulants by Geographic Region/Country
France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 50: European 14-Year Perspective for Anticoagulants by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 51: European Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 52: European Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 53: European 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

A. Market Analysis
Sanofi S.A.
A Key Player

B. Market Analytics
Table 54: French Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 55: French Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 56: French 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4b. GERMANY
A. Market Analysis
Product Launches
Strategic Corporate Developments
Focus on Select Players
B. Market Analytics
Table 57: German Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 58: German Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 59: German 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4c. ITALY
Market Analysis
Table 60: Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 61: Italian Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 62: Italian 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A. Market Analysis
Stroke Statistics
Opportunity Indicator for Anticoagulants
NICE Guidelines Promote NOAC Usage
Strategic Corporate Development
GlaxoSmithKline Plc.
A Key Player
B. Market Analytics
Table 63: The UK Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 64: The UK Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 65: The UK 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 66: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 67: Spanish Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 68: Spanish 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4f. RUSSIA
Market Analysis
Table 69: Russian Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 70: Russian Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 71: Russian 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE
A. Market Analysis
B. Market Analytics
Table 72: Rest of European Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 73: Rest of European Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 74: Rest of European 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A. Market Analysis
B. Market Analytics
Table 75: Population Statistics in Select Asian Countries & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)
Table 76: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country
China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 77: Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country
China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 78: Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic Region/Country
Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 79: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 80: Asia-Pacific Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 81: Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5a. CHINA
A. Market Analysis
Favorable Reimbursement for NOACs
LMWH
The leading Heparin Segment
Table 82: Chinese Import & Export Volumes and Values of Heparin & its Salts (2013, 2014 & 2015): Total Import Volume & Total Export Volume (in Kg); and Total Import Value & Total Export Value (in US$)
Product Approval
Strategic Corporate Development
B. Market Analytics
Table 83: Chinese Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 84: Chinese Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 85: Chinese 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5b. INDIA
A. Market Analysis
Abbott India Limited
A Key Player
B. Market Analytics
Table 86: Indian Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 87: Indian Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 88: Indian 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC
Market Analysis
Table 89: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 90: Rest of Asia-Pacific Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through
6. LATIN AMERICA
Market Analysis
Table 92: Latin American Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country
Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 93: Latin American Historic Review for Anticoagulants by Geographic Region/Country
Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 94: Latin American 14-Year Perspective for Anticoagulants by Geographic Region/Country
Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 95: Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 96: Latin American Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 97: Latin American 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

6a. BRAZIL
Market Analysis
Table 98: Brazilian Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 99: Brazilian Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 100: Brazilian 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

6b. REST OF LATIN AMERICA
Market Analysis
Table 101: Rest of Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 102: Rest of Latin American Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 103: Rest of Latin American 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD
A. Market Analysis
Teva Pharmaceutical Industries Ltd
A Key Player (Israel)

B. Market Analytics
Table 104: Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 105: Rest of World Historic Review for Anticoagulants by Product Type
Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 106: Rest of World 14-Year Perspective for Anticoagulants by Product Type
Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 51 (including Divisions/Subsidiaries 59)
The United States (25)
Canada (1)
Japan (3)
Europe (13)
- France (1)
- Germany (3)
- The United Kingdom (4)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (12)
Africa (1)
Middle East (4)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/338487/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anticoagulants - Global Strategic Analysis
Web Address: http://www.researchandmarkets.com/reports/338487/
Office Code: SCBR9VL5

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 6930</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td></td>
<td>USD 9405</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users:</td>
<td></td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB985308313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World